These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 3536093)
1. The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice. Dullens HF; Vuist W; Van der Maas M; Den Otter W Cancer Immunol Immunother; 1986; 23(2):113-8. PubMed ID: 3536093 [TBL] [Abstract][Full Text] [Related]
2. Specific tumoricidal activity of cytotoxic macrophages and cytotoxic lymphocytes. Dullens HF; Schakenraad S; Oostdijk A; Vuist W; Van der Maas M; Den Otter W Cancer Immunol Immunother; 1986; 22(2):100-6. PubMed ID: 3487380 [TBL] [Abstract][Full Text] [Related]
3. Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice. De Weger RA; Wilbrink B; Moberts RM; Mans D; Oskam R; Den Otter W Cancer Immunol Immunother; 1987; 24(1):25-36. PubMed ID: 3493070 [TBL] [Abstract][Full Text] [Related]
4. Differences in the induction of macrophage cytotoxicity by the specific T lymphocyte factor, specific macrophage arming factor (SMAF), and the lymphokine, macrophage activating factor (MAF). De Groot JW; De Weger RA; Vandebriel RJ; Den Otter W Immunobiology; 1989 Jun; 179(2-3):131-44. PubMed ID: 2676851 [TBL] [Abstract][Full Text] [Related]
5. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages. Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728 [TBL] [Abstract][Full Text] [Related]
6. The induction of lymphocytes with the capacity to render macrophages cytotoxic in an allogeneic murine system. De Weger RA; Pels E; Den Otter W Immunology; 1982 Nov; 47(3):541-50. PubMed ID: 6215342 [TBL] [Abstract][Full Text] [Related]
7. A macrophage factor enhancing the systemic anti-tumour effect of T lymphocytes. van Loveren H; de Groot JW; Koten JW; Piersma AH; de Weger RA; den Otter W Immunobiology; 1984 Mar; 166(2):118-30. PubMed ID: 6609876 [TBL] [Abstract][Full Text] [Related]
8. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages. Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice. Fuyama S; Yamamoto H; Fujii Y; Arai S Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480 [TBL] [Abstract][Full Text] [Related]
10. Effector phenotypes and mechanisms of antitumor immune reactivity of tumor-immunized and tumor-bearing mice in two syngeneic tumors. Fuyama S; Komatsu H; Arai S Cell Immunol; 1991 Oct; 137(1):200-15. PubMed ID: 1679379 [TBL] [Abstract][Full Text] [Related]
11. Macrophage tumoricidal activity as a possible antitumor mechanism associated with the local injection of allogeneic spleen cells into rats. Kawase I; Komuta K; Namba M; Yokota S; Ogura T; Kishimoto S Cancer Res; 1986 Mar; 46(3):1047-54. PubMed ID: 3510719 [TBL] [Abstract][Full Text] [Related]
12. Schizophyllan (SPG)-treated macrophages and anti-tumor activities against syngeneic and allogeneic tumor cells. I. Characteristics of SPG-treated macrophages. Sugawara I; Lee KC; Wong M Cancer Immunol Immunother; 1984; 16(3):137-44. PubMed ID: 6322974 [TBL] [Abstract][Full Text] [Related]
13. Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejection. Dullens HF; De Weger RA; Van der Maas M; Den Besten PJ; Vandebriel RJ; Den Otter W Cancer Immunol Immunother; 1989; 30(1):28-33. PubMed ID: 2598173 [TBL] [Abstract][Full Text] [Related]
14. Correlation between increase in Ia-bearing macrophages and induction of T cell-dependent antitumor activity by Lactobacillus casei in mice. Kato I; Yokokura T; Mutai M Cancer Immunol Immunother; 1988; 26(3):215-21. PubMed ID: 3133111 [TBL] [Abstract][Full Text] [Related]
15. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice. Fujii T; Igarashi T; Kishimoto S J Natl Cancer Inst; 1987 Mar; 78(3):509-17. PubMed ID: 2950265 [TBL] [Abstract][Full Text] [Related]
16. Sensitization of T lymphocytes in vitro by syngeneic macrophages fed with tumor antigens. Treves AJ; Schechter B; Cohen IR; Feldman M J Immunol; 1976 Apr; 116(4):1059-64. PubMed ID: 1082902 [TBL] [Abstract][Full Text] [Related]
17. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level. Sensi M; Orosz CG; Bach FH J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778 [TBL] [Abstract][Full Text] [Related]
18. Lymphocyte-induced macrophage cytotoxicity. Production of specific macrophage arming factor by sensitized Lyt 1+2+ T-lymphocytes. Pels E; De Weger RA; Den Otter W Int Arch Allergy Appl Immunol; 1984; 74(2):140-6. PubMed ID: 6609130 [TBL] [Abstract][Full Text] [Related]
19. Leukocyte subpopulations elicited by a nontumorigenic variant of B16 melanoma: their role in direct rejection of the melanoma and in prevention of tumorigenesis in Winn assays. Calvelli TA; Freedman VH; Silverstein SC; Silagi S J Exp Med; 1982 Dec; 156(6):1723-38. PubMed ID: 6983560 [TBL] [Abstract][Full Text] [Related]
20. Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumor bearing mice. Maas RA; Becker MJ; Weimar IS; De Nooy JC; Dullens HF; Den Otter WD Immunobiology; 1993 Jul; 188(3):281-92. PubMed ID: 7901148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]